Shire Continues to Deliver Excellent Growth From Cor...(91% of totalrevenues (2008: 92%). Exclud...),Health

    Product Highlights

                                                                          US
                                                                     Average
                                                     CER     US Rx  Quarterly
                                         Sales  Growth(2) Growth(1)   Market
    Product                 Sales $M  Growth(2)       (3)       (2)  Share(1)
    Specialty
    Pharmaceuticals
    VYVANSE                    129.0       34%       34%       57%       13%
    DAYTRANA                    17.4       -4%       -4%      -12%        1%
    EQUASYM                      9.2       n/a       n/a    n/a(5)    n/a(5)
    LIALDA / MEZAVANT           65.4       62%       63%       34%       17%
    PENTASA                     51.3        4%        4%       -3%       16%
    FOSRENOL                    47.7       11%       14%       -3%        8%
    XAGRID(R)                   21.5       11%       18%    n/a(5)    n/a(5)

    ADDERALL XR                 70.9      -74%      -74%      -59%        8%

    Human Genetic Therapies
    ELAPRASE                    90.9       16%       20%    n/a(4)    n/a(4)
    REPLAGAL                    48.3        8%       15%    n/a(5)    n/a(5)
    FIRAZYR                      1.8         -         -    n/a(5)    n/a(5)

    (1) Product specific prescription data is provided by IMS Health ("IMS")
        National Prescription Audit, a leading global provider of business
        intelligence for the pharmaceutical and healthcare industries. All
        other US market share data stated in the text below is also provided
        by IMS.
    (2) Compared to Q3 2008.
    (3) CER growth, which is a Non GAAP measure, is calculated after
        restating Q3 2009 results using Q3 2008 average foreign exchange
        rates.
    (4) I
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease